Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEN-COV in Transplants from COVID-19 Positive Donors
NCT05157997Phase 1Withdrawn
- Sponsor
- Northwell Health
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of casirivimab and imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Northwell Health. Primary endpoint: Monitoring for SARS-CoV-2 infection at 30 days. Planned start Jan 2022; status: withdrawn.
02
Drugs
casirivimabimdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05157997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157997.